Genkyotex, a Geneva, Switzerland and Archamps, France-based developer of selective NOX inhibitors, completed a CHF20m ($21m) Series D financing.
The round was led by NeoMed Management, who along with co-leads VI Partners and BioMedInvest were new investors. Major existing investors Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners were also participants. In conjunction with the funding, Dr. Claudio Nessi of NeoMed will join Genkyotex’s Board.
The company intends to use the funds to complete a Phase 2 trial of GKT137831 in diabetic nephropathy, advance a second drug into Phase 1 trials, and broaden its pipeline of NOX inhibitors.
Led by Dr. Ursula Ney, CEO, Genkyotex aims to unlock the potential of selective NOX enzyme inhibition to discover and develop a pipeline of drugs for hard to treat chronic diseases. The company expects to report top-line data from the Phase 2a study of its NOX1&4 inhibitor GKT137831 in mid-2015. Its NOX1&4 inhibitors have shown potential in difficult-to-treat fibrotic and inflammatory disorders of the kidney, liver, lung and skin.